Sophia Genetics, Synnovis Partner on UK Blood-Based Cancer Testing
MT Newswires Live
May 13
Sophia Genetics (SOPH) said Wednesday it is partnering with pathology provider Synnovis to launch liquid biopsy testing for lung and breast cancer patients in the United Kingdom.
The diagnostic tool identifies genomic changes through a single blood sample to help doctors select specific therapies up to 2 weeks faster than traditional methods, the company said.
Both organizations expect to perform the analysis for roughly 7,000 patients every year as part of a national health program, Sophia Genetics said.
The technology uses artificial intelligence to examine tumor DNA and includes features to reduce the occurrence of incorrect results, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.